SPOTLIGHT: FDA asks Adams Respiratory for more info


Adams Respiratory Therapeutics announced that the FDA is looking for more information before it can issue full approval of Mucinex with codeine for coughs. The company says it plans to meet with regulators to discuss the approvable letter. Release

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.